MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

TRAM-34

CAS No. : 289905-88-0

MCE 站：TRAM-34

产品活性：TRAM-34 是一种选择性的钙激活 K⁺ 通道 (IKCa1)阻断剂，K_d 为 20 nM。

研究领域：Membrane Transporter/Ion Channel

作用靶点：Potassium Channel

In Vitro: TRAM-34 selectively blocks the IKCa1 current (K_d=25 nM), TRAM-34 also blocks IKCa1 currents in human T84 colonic epithelial cells with equivalent potency (K_d=22 nM). TRAM-34 inhibits the cloned and the native IKCa1 channel in human T lymphocytes with a K_d of 20-25 nM and is 200- to 1,500-fold selective over other ion channels. The dose-response curve reveals a K_d of 20±3 nM and a Hill coefficient of 1.2 with 1 μM calcium in the pipette. TRAM-34, a specific inhibitor of K_Ca 3.1 channels increased or decreased cell proliferation depending on the concentration. At intermediate concentrations (3-10 ?M) TRAM-34 increased cell proliferation, whereas at higher concentrations (20-100 ?M) TRAM-34 decreased cell proliferation. The enhancement of cell proliferation caused by TRAM-34 is blocked by the oestrogen receptor antagonists ICI182,780 and tamoxifen. TRAM-34 also increases progesterone receptor mRNA expression, decreased oestrogen receptor-α mRNA expression and reduced the binding of radiolabelled oestrogen to MCF-7 oestrogen receptor, in each case mimicking the effects of 17β-oestradiol.

In Vivo: Mice (n=5) injected intravenously with a single dose of TRAM-34 (0.5 mg/kg; 29 μM) appeared clinically normal during the 7-day study. The body-weight data of the TRAM-34-treated group (day 1:17.8 g; day 7: 27.0 g) are similar to control mice injected with the vehicle (day 1: 17.4 g; day 7: 23.4 g). Collectively, data from these limited toxicity studies suggest that TRAM-34 is not acutely toxic at ≈500-1,000 times the channel-blocking dose.Treatment with TRAM-34 results in a significant reduction in hematoxylin & eosin (H&E) defined lesion area with the mean infarct size being reduced from 22.6±3.6% in the controls (n=8) to 11.3±2.8% in rats treated with 10 mg/kg TRAM-34 (n=6, mean±s.e.m., P=0.039) and to 8.1±1.9% in rats treated with 40 mg/kg TRAM-34 (n=8; P=0.004). The treatment also tended to reduce brain shrinkage. However, the results are only statistically significant with 40 mg/kg TRAM-34 (P=0.013), but not for the 10 mg/kg group (P=0.11).

相关产品：Bioactive Compound Library Plus  |  Membrane Transporter/Ion Channel Compound Library  |  Nigericin sodium salt  |  BAPTA-AM  |  Rosuvastatin Calcium  |  SKF-96365 hydrochloride  |  Glibenclamide  |  SCH-23390 hydrochloride  |  Tetrandrine  |  Amiodarone hydrochloride  |  Ifenprodil tartrate  |  Minoxidil  |  Diazoxide  |  20(S)-Ginsenoside Rg3  |  Senicapoc  |  Tannic acid  |  DCPIB  |  Astemizole  |  Ketanserin  |  Quinine  |  E-4031  |  Terfenadine  |  Hydrochlorothiazide  |  GW9508  |  Daurisoline  |  Nicorandil  |  Dofetilide  |  Pinacidil monohydrate  |  ML277  |  Tolbutamide  |  Almitrine mesylate  |  Flufenamic acid

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。